STACK · ◇ Layered protocol · 4 tiers
Sexual Health & Intimacy.
The only FDA-approved peptide for sexual desire — plus the partners that complete the picture.
Layered · goal-fork + additive
Hook facts
The science, in one line each.
PT-141 is the only FDA-approved drug that works by targeting the brain's desire circuitry directly — not blood vessels, not hormones. It was accidentally discovered during research on a tanning peptide, when test subjects unexpectedly reported spontaneous sexual arousal as a side effect.
When to skip it
Read this first.
Individuals with cardiovascular disease, high blood pressure, or those taking medications that affect blood pressure should consult a physician before use — PT-141 produces transient blood pressure increases. Not for use alongside other melanocortin agonists. The Pro tier (PT-141 + Oxytocin) requires oxytocin to be available in the catalogue; the compound is currently in soft launch. The Adjunct tier (CJC/Ipa) is not for users with active acromegaly, pituitary disorders, or a personal or family history of pituitary tumours.
Always cleared with your concierge before protocol start.
Why this works
The strongest evidence.
PT-141 (bremelanotide) received FDA approval as Vyleesi in June 2019 — NDA 210557 — for hypoactive sexual desire disorder (HSDD) in pre-menopausal women at the 1.75 mg subcutaneous dose. This makes it the only FDA-approved peptide in the personalized-peptides catalogue for an explicitly sexual indication, and one of only two FDA-approved treatments for HSDD (alongside flibanserin/Addyi). The approval was based on Phase 3 data showing statistically significant improvements in desire scores and distress associated with low desire versus placebo, with a brain-based mechanism that works independently of hormonal status or vascular function. Oxytocin's role in sexual response is supported by a body of intranasal-administration trials showing enhanced orgasmic intensity, bonding behaviour, and prosocial connectivity — a distinct and complementary evidence base to PT-141's CNS desire-pathway data.
Layered protocol
Choose your tier.
A layered protocol — most tiers add to the last, with a fork or rotation where the data calls for it.
Female Desire
PT-141 (Bremelanotide)
Anyone whose primary concern is desire intensity — reduced libido, HSDD, antidepressant-induced sexual dysfunction, or e…
This fork is for desire. PT-141 (bremelanotide / Vyleesi) is FDA-approved for hypoactive sexual desire disorder in pre-menopausal women — the only FDA-approved peptide for sexual desire, and one of only two approved HSDD treatments on the market. It works on the brain's MC4R melanocortin pathway, activating the central arousal circuitry directly. Not vascular, not hormonal — a neurochemical desire signal. If low libido and reduced drive are the issue, this is the clinical-grade starting point.
Who it's for
Women with HSDD, post-menopausal libido decline, antidepressant-induced sexual dysfunction, or any woman wanting the FDA-approved brain-based approach to desire. This is the fork for users whose primary issue is desire intensity — the neurochemical signal that sex is wanted.
What to expect
On-demand arousal enhancement within 45 minutes to 2 hours of injection. Improved genital sensation and sexual desire. Most women report meaningful effect from the first or second dose at the FDA 1.75 mg dose. This fork is for desire — if the issue is emotional intimacy or orgasmic intensity rather than drive, the Pro tier (Oxytocin) is the distinct intervention.
Male Arousal
PT-141 (Bremelanotide)
Anyone whose primary concern is desire intensity — reduced libido, HSDD, antidepressant-induced sexual dysfunction, or e…
This fork is for arousal — the brain-based signal, not the vascular response. PT-141 acts on the MC4R pathway in the CNS: desire, arousal, and motivation for sex — not smooth-muscle vasodilation. This makes it a different tool from Viagra or Cialis, not a competitor. Men whose ED has a neurogenic or psychogenic dimension (performance anxiety, stress, medication side effects) are the target here — and in cases where PDE5i works partially, PT-141 can be layered under physician guidance for additive effect. The same compound, different pathway entirely.
Who it's for
Men with ED or reduced arousal that is driven by neurological, psychogenic, or mixed factors — particularly where PDE5 inhibitors (Viagra, Cialis) have been insufficient, produce side effects, or are contraindicated. This is the fork for men whose arousal issue has a central/neurogenic component, not purely vascular.
What to expect
On-demand arousal and erectile enhancement within 45 minutes to 2 hours. Operates via a different mechanism from PDE5 inhibitors — brain-based rather than vascular — so can be additive with them under physician guidance. First dose typically shows clear effect. If the issue is relational or intimacy-based rather than desire intensity, the Pro tier (Oxytocin) is the distinct route.
Desire & Connection
PT-141 (Bremelanotide)
Anyone whose primary concern is desire intensity — reduced libido, HSDD, antidepressant-induced sexual dysfunction, or e…
This is two different brain systems, not a dose escalation. PT-141 fires the MC4R desire pathway — the neurochemical signal that sex is wanted. Oxytocin fires the prosocial and bonding circuitry — trust, sensory amplification, orgasmic intensity, and post-coital connection. These are genuinely distinct axes: Oxytocin does not sharpen libido; PT-141 does not deepen relational presence. Together, they cover the full picture — the commercial Libida product (sublingual bremelanotide + oxytocin) is built on exactly this combination. Oxytocin is currently Coming Soon in this catalogue; when available, it slots directly into this tier as the bonding-layer complement.
Who it's for
Couples or individuals where the goal is emotional intimacy, orgasmic intensity, and interpersonal connection — not just libidinal drive. The Pro tier adds Oxytocin to the PT-141 desire signal, targeting the prosocial and bonding axis that PT-141 alone does not address. Oxytocin is in soft launch — Coming Soon.
What to expect
PT-141 provides the desire signal; Oxytocin enhances sensory perception, emotional bonding, and post-coital connection. The combination produces an experience qualitatively different from either agent alone — desire from PT-141's MC4R pathway, relational depth from Oxytocin's prosocial axis. This is not PT-141 with extra potency; it is PT-141 plus a separate brain system activated. Oxytocin availability required — currently Coming Soon.
Hormonal Foundation
+ sits on top of any tier above
Ipamorelin / CJC-1295 Blend
Users whose sexual issues are downstream of GH/IGF-1 decline, low energy, or body composition shifts. The hormonal-found…
This tier runs on a different axis entirely. The goal-fork above is about the desire signal — MC4R activation, central arousal, on-demand response. This Adjunct tier is about the hormonal foundation: GH/IGF-1 axis support over a 12-week cycle, restoring the substrate that drives baseline libido, energy, and body composition. If sexual function declined alongside declining energy, loss of muscle mass, worsening sleep, or body composition shifts, the issue may be hormonal-foundation rather than (or in addition to) desire-signal failure. CJC/Ipa does not produce the same effect as PT-141 — it doesn't fire the arousal pathway. It builds the environment in which that pathway operates more effectively over time.
Who it's for
Users whose sexual issues are downstream of a hormonal-foundation problem — GH/IGF-1 decline, low energy, or body composition shifts that have eroded baseline libido and sexual function over time. This is an orthogonal tier, not a dose escalation of the desire-pathway approach above.
What to expect
12-week CJC/Ipa cycle improves the hormonal environment for libido and sexual function. Body composition improvements, better energy substrate, and improved testosterone signalling environment all contribute over the cycle. This tier does not produce on-demand arousal effects — it addresses the root-cause hormonal foundation that makes the on-demand tiers more effective.
Compound roster
Every compound, briefed.
Each compound in this stack — what it does and where it fits.
PT-141 (bremelanotide) is a synthetic α-MSH analogue that acts as a selective agonist at MC4R — the melanocortin receptor subtype governing central arousal and sexual desire pathways in the brain. Unlike Melanotan-2, which is non-selective across MC1R and MC4R, PT-141's selectivity means it activates the desire pathway without the degree of pigmentation or nausea associated with the older compound. Crucially, PT-141 operates via the central nervous system, not the vascular system — its mechanism is entirely distinct from PDE5 inhibitors (Viagra, Cialis), which act peripherally on smooth muscle vasodilation. This makes it additive with PDE5i under physician guidance and the only tool in this stack for neurogenic or psychogenic arousal dysfunction. FDA-approved as Vyleesi for HSDD in pre-menopausal women at 1.75 mg subcutaneous; onset 45 minutes to 2 hours, duration 2–4 hours.
Best for · Anyone whose primary concern is desire intensity — reduced libido, HSDD, antidepressant-induced sexual dysfunction, or erectile/arousal dysfunction with a neurogenic or psychogenic component. The clinical anchor of this stack and the first choice when desire is the goal.
Pre-mixed CJC-1295 (no DAC) + Ipamorelin in a single vial. CJC-1295 acts on the GHRH receptor to extend the amplitude and duration of each GH pulse; Ipamorelin acts on the ghrelin receptor to trigger clean pulsatile GH release without cortisol or appetite side effects. When used as the Adjunct tier in this stack, the blend addresses the hormonal foundation layer — GH/IGF-1 axis support improves testosterone signalling environment, energy substrate, and body composition over 12+ weeks. The mechanism is orthogonal to PT-141's CNS desire pathway.
Best for · Users whose sexual issues are downstream of GH/IGF-1 decline, low energy, or body composition shifts. The hormonal-foundation layer that improves the environment in which on-demand PT-141 operates — not a substitute for it.
CJC-1295 without the Drug Affinity Complex modification — a GHRH analogue that binds the GHRH receptor on pituitary somatotrophs. The no-DAC form has a shorter half-life, producing discrete GH pulses that preserve natural pulsatile GH rhythm. Relevant in this stack as the Adjunct tier's GHRH component, supporting testosterone environment and energy substrate for sexual function over 12-week cycles.
Best for · Users who prefer to dose CJC and Ipamorelin as separate vials for precise independent titration in the Adjunct tier.
A ghrelin-mimetic growth hormone releasing peptide (GHRP) that binds the ghrelin receptor (GHSR-1a) — a completely different receptor pathway from CJC-1295's GHRH receptor. Ipamorelin triggers GH release without cortisol elevation, prolactin rise, or hunger spikes, making it the cleanest GH secretagogue in its class for most applications. In this stack's Adjunct tier, it contributes to the hormonal foundation supporting libido and sexual energy over time.
Best for · Standalone dosing in the Adjunct tier when prescribed separately; or combined with cjc-no-dac for users whose protocol calls for individual vials.
The most potent GHRH analogue in the catalogue and the only one with FDA approval — cleared for visceral fat reduction in HIV-associated lipodystrophy. Tesamorelin stimulates the GHRH receptor with higher output than CJC-1295, producing stronger GH pulses and corresponding improvements in body composition. In the sexual health context, it is relevant for users whose low sexual function is downstream of visceral adiposity, metabolic dysfunction, or body composition issues — by addressing those root causes, the hormonal environment for libido and sexual function improves.
Best for · Users with central adiposity or metabolic syndrome as a primary driver of declining sexual function — where treating the hormonal-environment root cause is the leverage point.
The science
Peer-reviewed findings.
Key research findings from the compounds in this stack.
Two pivotal Phase 3 trials demonstrated bremelanotide 1.75 mg SC significantly improved the number of satisfying sexual events and reduced HSDD-associated personal distress versus placebo in premenopausal women with HSDD.
SOURCE · Kingsberg et al., Journal of Sexual Medicine / PMC6819021 (2019)
Bremelanotide achieves ~100% subcutaneous bioavailability with median Tmax ~1 hour; at the approved 1.75 mg dose, it produces mean Cmax of 72.8 ng/mL and AUC of 276 hr·ng/mL, with plasma concentration plateau occurring at 7.5 mg (4.3× maximum recommended dose).
SOURCE · FDA Prescribing Information — Vyleesi (bremelanotide) NDA 210557
Protocol
How to run it.
Frequency
PT-141: 1.75 mg subcutaneous injection (FDA-approved dose for women) or 1–2 mg commonly used off-label in men. Administer 45 minutes to 2 hours before anticipated sexual activity. Maximum once per 24 hours. Not for daily scheduled use — PT-141 is on-demand, not continuous.
Duration
On-demand protocol — no cycling required. Some users run 3–4 doses per month consistently; others use as needed. No evidence of receptor desensitisation at typical once-per-24h use frequency. For the Adjunct tier (CJC/Ipa for hormonal foundation): standard 12-week cycle with 4-week break, administered before sleep.
Timing
45-minute to 2-hour onset window. Peak effect typically 2–4 hours post-injection. Plan accordingly. Nausea is the most common side effect (30–40% of users); taking with a light meal can mitigate. Oxytocin (Pro tier, when available) is typically intranasal, administered 30–45 minutes before sexual activity.
Cycling
On-demand use — no formal cycle required for PT-141. For adjunct tier (CJC/Ipa for hormonal foundation): standard 12-week cycle with 4-week break, administered before sleep.
Who it's for
Your profile.
Adults experiencing hypoactive sexual desire disorder (HSDD), libido decline related to aging or medication, or erectile and arousal dysfunction that hasn't responded adequately to conventional approaches. PT-141 is FDA-approved (as Vyleesi) specifically for HSDD in pre-menopausal women — making it the most legally and clinically validated entry point in this space. For men, it addresses the brain-based arousal pathway rather than vascular mechanisms, making it particularly relevant when PDE5 inhibitors (Viagra, Cialis) are insufficient or contraindicated. The stack is also highly relevant for couples where desire mismatch or medication-induced sexual side effects are the primary issue.
Timeline
What to expect.
- 01
Week 1–2
On-demand response is the primary effect — most users experience noticeable arousal enhancement within the first 1–2 doses. Female users typically report improved genital sensation and desire within the FDA-studied dose range. Male users commonly experience harder erections and stronger libido within the same window.
- 02
Week 6
With consistent on-demand use, the psychogenic component of desire often improves — some users report reduced performance anxiety and improved sexual self-confidence alongside the direct pharmacological effect. Adjunct tier (CJC/Ipa) users may notice improved energy, sleep quality, and mild body composition improvements by week 6.
- 03
Week 12
For users running the adjunct GH-axis protocol alongside on-demand PT-141, the hormonal foundation benefits compound: improved testosterone signalling environment, better energy substrate, and improved body composition all contribute to baseline libido and sexual function over time.
Stacking notes
How this combines.
This stack uses a goal-fork structure — the tiers are not a progression, they are parallel tracks for different goals. PT-141 (Female Desire or Male Arousal fork) addresses the central neurochemical desire signal via MC4R. Oxytocin (Pro tier, Coming Soon) addresses a completely different brain system — the prosocial and interpersonal-affective axis, trust, bonding, and orgasmic intensity. Choosing PT-141 is not weaker than choosing PT-141 + Oxytocin; it is a different goal entirely. If desire intensity is the issue, PT-141 is the answer. If intimacy, emotional connection, or orgasmic depth is the issue, Oxytocin is the distinct intervention — it does not sharpen the libidinal desire signal at all. The Adjunct tier (CJC/Ipa) is orthogonal to both: it works on the GH/IGF-1 hormonal foundation over 12+ weeks, improving the environment in which on-demand compounds operate. It is not the same axis as PT-141 and should not be treated as a dose escalation. Melanotan-2 is available for users who specifically want libido enhancement and UV-induced skin pigmentation simultaneously — but if libido alone is the goal, PT-141 (MC4R selective) is the cleaner choice; MT-2's non-selective MC1R/MC4R activity brings pigmentation and nausea as additional effects.